| |
Centre for Policy on Ageing | |
 | |
|
Economic evaluation of cholinesterase inhibitor therapy for dementia
— comparison of Alzheimer's disease and Dementia with Lewy bodies | | Author(s) | Anders Gustavsson, Rohan Van Der Putt, Linus Jönsson |
| Journal title | International Journal of Geriatric Psychiatry, vol 24, no 10, October 2009 |
| Pages | pp 1072-1078 |
| Source | http://www.interscience.wiley.com/journal/gps |
| Keywords | Dementia ; Drugs ; Costs [care] ; Cost effectiveness ; Evaluation ; Longitudinal surveys ; Oxfordshire. |
| Annotation | The aim of this study was to assess the cost effectiveness of cholinesterase inhibitor (ChEI) treatment in patients with Alzheimer's disease (AD) and Dementia with Lewy bodies (DLB). The authors used 4-month open label follow-up data from routine memory clinic patients in Oxfordshire. There were 852 patients with AD and 112 with DLB. They applied three predictive models to estimate clinical and economic outcomes at five years, comparing AD and DLB patients with hypothetical untreated controls. The mean improvement in Mini Mental State Examination (MMSE) in the 852 AD patients was 0.57 (SD 3.4) at 4 months, and in the subgroup with baseline MMSE of 10-20 (moderate) was 1.6 (SD 3.7). Overall, the 112 DLB patients improved by 1.4 (SD 3.7). DLB patients with an MMSE score of 10-20 improved by 3.1 (SD 4.5) points. These efficacy data were input into the SHTAC (Southampton Health Technology Assessments Centre), microsimulation and Markov models and produced estimated costs per QALY gained (CQG) for all AD of £194,066, £67,904 and £123,935 respectively. In comparison, the CQGs for all DLB were £46,794, £2,706 and £35,922. For the moderate subgroups, only the SHTAC and microsimulation models were applicable. These gave CQG estimates for moderate AD of £39,664 and cost saving respectively. For moderate DLB, both estimates were cost saving. The cost per QALY (quality adjusted life year) gained of cholinesterase treatment of all patients with DLB (including those with MMSE outside the 10-20 range) is comparable to that of patients with moderate AD, and is probably cost saving. (KJ/RH). |
| Accession Number | CPA-100109210 A |
| Classmark | EA: LLD: QDC: WEC: 4C: 3J: 8O |
Data © Centre for Policy on Ageing |
|
| ...from the Ageinfo database published by Centre for Policy on Ageing. |
| |
|